City Therapeutics Submits Clinical Trial Application for CITY-FXI, an Investigational RNAi Therapeutic Targeting Factor XI for the Treatment of Thromboembolic Diseases City Therapeutics, Inc., a pioneering biopharmaceutical company focused on advancing the field of RNA interference (RNAi)-based medicine, today announced…
AstraZeneca’s FASENRA Demonstrates Statistically Significant Clinical Benefit in Phase III NATRON Trial for Hypereosinophilic Syndrome AstraZeneca has announced positive full results from its pivotal Phase III NATRON clinical trial evaluating FASENRA (benralizumab) as a therapeutic option for patients living with…
ONDEX Automation Acquires PlantOPS Consulting, Expands MES and Life Sciences Capabilities ONDEX Automation has announced the acquisition of PlantOPS Consulting, a well-established specialist in Manufacturing Execution System (MES) consulting and implementation for pharmaceutical, biotechnology, and medical technology companies. The transaction…
NMDP and CIBMTR to Present Research Advancing Transplant Access and Cell Therapy Innovation at ASH 2025 NMDP℠, a leading global nonprofit dedicated to advancing cell therapy, and the CIBMTR® (Center for International Blood and Marrow Transplant Research®) announced that they…
Zetagen Therapeutics Announces Presentation of Promising Phase 2a Data Demonstrating Complete Responses in Metastatic Breast Cancer Bone Lesions at 2025 SABCS Zetagen Therapeutics, a privately held clinical-stage biopharmaceutical company developing innovative, targeted therapies for both primary and metastatic breast cancer,…
Vistagen Completes Phase 3 PALISADE-3 Trial Evaluating Fasedienol for Acute Treatment of Social Anxiety Disorder Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company advancing neuroscience through innovative nose-to-brain therapeutics, announced the completion of patient participation in the randomized, double-blind, placebo-controlled…
CHMP Recommends Saphnelo Subcutaneous Administration for SLE in the EU, Offering Convenient Self-Administration Option AstraZeneca has announced that its fully human monoclonal antibody Saphnelo (anifrolumab) has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP)…
CatalYm Unveils Promising Phase 2 GDFATHER-NEO Data: Visugromab Enhances Anti-Tumor Activity with PD-1 Inhibition in Neoadjuvant Muscle-Invasive Bladder Cancer CatalYm, a pioneering biotechnology company recognized globally for its focus on neutralizing Growth Differentiation Factor-15 (GDF-15) in cancer and cachexia, has…
raditional Medicine Gains Prominence at World Health Summit 2025 For the first time in its history, the World Health Summit in 2025 highlighted traditional medicine as a core topic, with two dedicated sessions held in Berlin, Germany. These sessions underscored…
Chemist Lutz Ackermann Honored With Bayer Foundation’s Hansen Family Award; Four Young Researchers Receive Early Excellence in Science Awards Georg-August University Göttingen chemist Prof. Dr. Lutz Ackermann has been awarded the €75,000 Hansen Family Award from the Bayer Foundation for…
CVS Health Expands Access to Affordable Fertility Treatments Nationwide CVS Health (NYSE: CVS) has announced a major step toward improving access to fertility care and making fertility treatments more affordable for Americans. Through its CVS Specialty Pharmacy network and more…
Novartis’ Fabhalta® (Iptacopan) Achieves Positive Phase III Results, Marking Major Progress in Slowing Kidney Function Decline in Patients With IgA Nephropathy Novartis announced encouraging final results from its pivotal Phase III APPLAUSE-IgAN clinical trial, evaluating the investigational oral therapy Fabhalta®…